Disease Hospital Pharmaceutical Radiation 
Imaging Technology
JANUARY 8, 2024
Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.
Imaging Technology
AUGUST 31, 2023
Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. actinium-225 (Ac-225).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
APRIL 2, 2024
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics.
Imaging Technology
JULY 5, 2023
Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. NorthStar is positioned to be the first commercial-scale producer of n.c.a.
AuntMinnie
AUGUST 5, 2024
Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. It certainly doesn't help matters that the disease has been linked to gadolinium-based contrast agents, a ubiquitous tool in the MR armamentarium. Louis hospital. In 2006 the U.S.
AuntMinnie
JUNE 3, 2024
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology. led by Harshad Kulkarni, MD, as principal investigator.
Imaging Technology
APRIL 3, 2023
This unit will enable us to develop and manufacture patient doses for pharmaceutical or biotechnology companies as well as share our radiopharmaceutical development and commercialization expertise with them where they may require additional infrastructure, resources or the specialized knowledge required for complex radiopharmaceutical development.
Expert insights. Personalized for you.
105 
Let's personalize your content